Ataraxis AI

Ataraxis AI is a clinical artificial intelligence company headquartered in New York, United States, focused on making disease predictable and personalizing treatment selection. The company spun out of New York University in 2023 and raised a seed round that same year. Its stated mission is to empower physicians with advanced multi-modal tools that pinpoint the most effective treatments and improve patient outcomes. Ataraxis develops AI methods that integrate information from multiple digital data modalities. Its systems discover novel clinical, morphological, and molecular features of patients and their disease, capturing the heterogeneity of cancer beyond a single data type. The company's proprietary technology analyzes multi-modal patient data to assess disease aggressiveness, predict the risk of cancer recurrence or death, and estimate how different treatment options may benefit different patients. Its flagship offering is Ataraxis Breast, described as an AI-native platform with clinically validated prognostic and predictive tools for breast cancer. All Ataraxis tests are built on AI foundation models, such as Falcon, trained with hundreds of millions of pan-cancer pathology slide images to extract tumor morphology information that correlates with patient outcomes and treatment response. The company emphasizes same-day turnaround, delivering analysis results within 24 hours of receiving patient data, and sparing valuable tissue because physical tissue is not exhausted and no additional histology preparation is necessary. Ataraxis was founded by physician-scientist Jan Witowski, who serves as Chief Executive Officer, and Krzysztof Geras, who serves as Chief Scientific Officer. Witowski has over ten years of medical image processing experience and previously worked at Harvard Medical School, Massachusetts General Hospital, and NYU Langone Health. Geras is an Assistant Professor at NYU Grossman School of Medicine, Department of Radiology, and is affiliated with the NYU Center for Data Science and Courant Institute of Mathematical Sciences, with prior experience at JP Morgan, Microsoft, and Amazon. The company's story includes the 2024 development and clinical validation of Ataraxis Breast, the first AI-native test for breast cancer, and Kestrel, a state-of-the-art foundation model for digital pathology. In 2025, Ataraxis raised $20.4 million in Series A funding. The company operates as a private, venture-backed entity and is building a team of scientists, engineers, and physicians to transform precision medicine.

Ataraxis AI was founded in 2023 as a spin-out from New York University, accompanied by a seed funding round. The company was established to commercialize artificial intelligence methods for precision medicine, with an initial focus on oncology. Its founding team combined clinical and machine learning expertise: Jan Witowski, a physician-scientist with over a decade of medical image processing experience and prior roles at Harvard Medical School, Massachusetts General Hospital, and NYU Langone Health, and Krzysztof Geras, an assistant professor at NYU Grossman School of Medicine's Department of Radiology with affiliations at the NYU Center for Data Science and Courant Institute of Mathematical Sciences, and industry experience at JP Morgan, Microsoft, and Amazon. In 2024, the company developed and clinically validated Ataraxis Breast, which it describes as the first AI-native test for breast cancer, alongside Kestrel, a state-of-the-art foundation model for digital pathology. These developments built on the company's approach of using AI foundation models trained on hundreds of millions of pan-cancer pathology slide images to extract tumor morphology features correlated with patient outcomes and treatment response. In 2025, Ataraxis AI raised $20.4 million in Series A funding, supporting further development and commercialization of its clinical AI platform. The company continues to operate from New York as a private, venture-backed enterprise, aiming to personalize treatment by predicting patient outcomes and treatment response through multi-modal data analysis.

• Ataraxis spun out of New York University and raised a Seed round.

• Developed and clinically validated Ataraxis Breast, the first AI-native test for breast cancer, and Kestrel, a state-of-the-art foundation model for digital pathology.

• Raised $20.4 million in Series A funding.

AI-native precision medicine for oncology, delivering clinically validated prognostic and predictive tests with same-day turnaround and tissue-sparing workflows.

• Ataraxis Breast

  AI-native platform with clinically validated prognostic and predictive tools for breast cancer.

• Falcon

  AI foundation model trained with hundreds-of-millions of pan-cancer pathology slide images.

• Kestrel

  State-of-the-art foundation model for digital pathology.

1. 1Ataraxis AI | Homepageataraxis.ai
2. 2Ataraxis AI | About Usataraxis.ai
3. 3Ataraxis AI - Wikidatawikidata.org